Celgene European Investment Co Llc - Net Worth and Insider Trading
Celgene European Investment Co Llc Net Worth
The estimated net worth of Celgene European Investment Co Llc is at least $190 Million dollars as of 2024-04-27. Celgene European Investment Co Llc is the 10% Owner of Agios Pharmaceuticals Inc and owns about 5,867,279 shares of Agios Pharmaceuticals Inc (AGIO) stock worth over $185 Million. Celgene European Investment Co Llc is also the 10% Owner of Epizyme Inc and owns about 3,674,640 shares of Epizyme Inc (EPZM) stock worth over $5 Million. Details can be seen in Celgene European Investment Co Llc's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Celgene European Investment Co Llc has not made any transactions after 2017-04-24 and currently still holds the listed stock(s).
Transaction Summary of Celgene European Investment Co Llc
Celgene European Investment Co Llc Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Celgene European Investment Co Llc owns 2 companies in total, including Agios Pharmaceuticals Inc (AGIO) , and Epizyme Inc (EPZM) .
Insider Ownership Summary of Celgene European Investment Co Llc
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| AGIO | Agios Pharmaceuticals Inc | 2019-11-12 | 10 percent owner |
| EPZM | Epizyme Inc | 2014-02-10 | 10 percent owner |
Celgene European Investment Co Llc Latest Holdings Summary
Celgene European Investment Co Llc currently owns a total of 2 stocks. Among these stocks, Celgene European Investment Co Llc owns 5,867,279 shares of Agios Pharmaceuticals Inc (AGIO) as of April 24, 2017, with a value of $185 Million and a weighting of 97.16%. Celgene European Investment Co Llc also owns 3,674,640 shares of Epizyme Inc (EPZM) as of February 10, 2014, with a value of $5 Million and a weighting of 2.84%.
Latest Holdings of Celgene European Investment Co Llc
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| AGIO | Agios Pharmaceuticals Inc | 2017-04-24 | 5,867,279 | 31.49 | 184,760,616 |
| EPZM | Epizyme Inc | 2014-02-10 | 3,674,640 | 1.47 | 5,401,721 |
Holding Weightings of Celgene European Investment Co Llc
Celgene European Investment Co Llc Form 4 Trading Tracker
According to the SEC Form 4 filings, Celgene European Investment Co Llc has made a total of 0 transactions in Agios Pharmaceuticals Inc (AGIO) over the past 5 years. The most-recent trade in Agios Pharmaceuticals Inc is the acquisition of 624,575 shares on April 24, 2017, which cost Celgene European Investment Co Llc around $31 Million.
According to the SEC Form 4 filings, Celgene European Investment Co Llc has made a total of 0 transactions in Epizyme Inc (EPZM) over the past 5 years. The most-recent trade in Epizyme Inc is the acquisition of 340,000 shares on February 10, 2014, which cost Celgene European Investment Co Llc around $10 Million.
Insider Trading History of Celgene European Investment Co Llc
- 1
Celgene European Investment Co Llc Trading Performance
GuruFocus tracks the stock performance after each of Celgene European Investment Co Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Celgene European Investment Co Llc is -0.01%. GuruFocus also compares Celgene European Investment Co Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Celgene European Investment Co Llc within 3 months outperforms 2 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Celgene European Investment Co Llc's insider trading performs compared to the benchmark.
Performance of Celgene European Investment Co Llc
Average Return
27.72%
Outperforming Transactions
50%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 1.3 | -0.01 | 21.06 | 27.72 | 3.74 | -7.86 |
| Relative Return to S&P 500(%) | -0.17 | -4.47 | 13.8 | 14.27 | -4.63 | -16.52 |
Celgene European Investment Co Llc Ownership Network
Ownership Network List of Celgene European Investment Co Llc
Ownership Network Relation of Celgene European Investment Co Llc
Celgene European Investment Co Llc Owned Company Details
What does Agios Pharmaceuticals Inc do?
Who are the key executives at Agios Pharmaceuticals Inc?
Celgene European Investment Co Llc is the 10 percent owner of Agios Pharmaceuticals Inc. Other key executives at Agios Pharmaceuticals Inc include Chief Legal Officer James William Burns , Chief Medical Officer Sarah Gheuens , and Principal Accounting Officer Washburn Theodore James Jr. .
Agios Pharmaceuticals Inc (AGIO) Insider Trades Summary
Over the past 18 months, Celgene European Investment Co Llc made no insider transaction in Agios Pharmaceuticals Inc (AGIO). Other recent insider transactions involving Agios Pharmaceuticals Inc (AGIO) include a net sale of 205,692 shares made by David P Schenkein , a net sale of 8,791 shares made by Washburn Theodore James Jr. , and a net sale of 14,160 shares made by James William Burns .
In summary, during the past 3 months, insiders sold 93,495 shares of Agios Pharmaceuticals Inc (AGIO) in total and bought 0 shares, with a net sale of 93,495 shares. During the past 18 months, 358,881 shares of Agios Pharmaceuticals Inc (AGIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 358,881 shares.
Agios Pharmaceuticals Inc (AGIO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Agios Pharmaceuticals Inc Insider Transactions
Celgene European Investment Co Llc Mailing Address
Above is the net worth, insider trading, and ownership report for Celgene European Investment Co Llc. You might contact Celgene European Investment Co Llc via mailing address: 86 Morris Avenue, Summit Nj 07901.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
